SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives
Vascular Health and Risk Management
doi 10.2147/vhrm.s83088
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2016
Authors
Publisher
Informa UK Limited